Through-the-scope enteral metal stent placement using a short-type single-balloon enteroscope for malignant surgically reconstructed jejunal stenosis (with video)

2016 ◽  
Vol 28 (7) ◽  
pp. 758-758 ◽  
Author(s):  
Kosuke Minaga ◽  
Masayuki Kitano ◽  
Mamoru Takenaka
2018 ◽  
Vol 06 (11) ◽  
pp. E1330-E1335 ◽  
Author(s):  
Kei Yane ◽  
Akio Katanuma ◽  
Tsuyoshi Hayashi ◽  
Kuniyuki Takahashi ◽  
Toshifumi Kin ◽  
...  

AbstractEndoscopic enteral self-expandable metal stent (SEMS) placement is a useful alternative treatment option for malignant afferent limb syndrome (ALS). We investigated the safety, efficacy, and follow-up results of enteral SEMS placement using a single-balloon enteroscope for the treatment of malignant ALS.


Endoscopy ◽  
2020 ◽  
Vol 52 (09) ◽  
pp. E337-E338
Author(s):  
Angelo Caruso ◽  
Salvatore Russo ◽  
Giuseppe Grande ◽  
Flavia Pigò ◽  
Santi Mangiafico ◽  
...  

2011 ◽  
Vol 45 (10) ◽  
pp. 1307-1307 ◽  
Author(s):  
Sarah R Peppard ◽  
Bethanne M Held-Godgluck ◽  
Richard Beddingfield

Objective: To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. Case Summary: A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed Stephens-Johnson syndrome 6 years earlier following Clopidogrel administration, characterized by erythematous plaques and subsequent desquamation of the hands and feet; Clopidogrel was discontinued and he was subsequently treated with ticlopidine in addition to aspirin. The third-generation thienopyridine prasugrel was initiated as a therapeutic alternative to Clopidogrel after placement of a bare metal stent; a 60-mg dose was administered after extubation, followed by 10 mg/day. No signs of allergic reaction were observed in the days, weeks, and months following administration. Discussion: Thienopyridines, specifically Clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents. One study demonstrated that 27% of patients who developed an allergic or hematologic reaction to Clopidogrel developed a similar reaction to ticlopidine. Other therapeutic options for patients with Clopidogrel hypersensitivity who are undergoing a percutaneous coronary intervention with stent placement include Clopidogrel desensitization, warfarin plus aspirin, cilostazol, ticagrelor, and ticlopidine. However, these options are limited by efficacy and/or toxicity. With its approval in 2009, prasugrel has become a potential treatment option. Conclusions: Prasugrel may be considered a therapeutic alternative in some patients allergic or intolerant to Clopidogrel, but additional data are warranted to make a strong conclusion.


Sign in / Sign up

Export Citation Format

Share Document